EICHORPublic-registry site landscape for NCT03850782, “Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension”, a Open-Angle Glaucoma study sponsored by AbbVie. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03850782 (registry record) |
| Study title | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension |
| Official title | A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension |
| Sponsor | AbbVie |
| Condition(s) | Open-Angle Glaucoma; Ocular Hypertension |
| Phase | PHASE3 |
| Listed sites | 108 |
| Intervention(s) | Bimatoprost (SR) |
| Site countries | United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland |
Patient-friendly overview of this study: eichor.com/study/NCT03850782.
Eichor generates a preliminary site-risk snapshot for NCT03850782 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Open-Angle Glaucoma trials
More from AbbVie
← Eichor home · All tracked trials · Open-Angle Glaucoma studies · Weekly briefs
